Pancreatic Cancer Research

ResearcherMayo ClinicActive in the last 2 years

Federico Canzian

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-4261-4583; OpenAlex author ID A5004285350. Sources: OpenAlex.

Their work

Papers
82 (first author 1, last author 19)
Trials
0
Grants
0
Labs led
1
Collaborators
165
Papers, trials and grants by year

2011: 1 paper · 2012: 2 papers · 2013: 6 papers · 2014: 4 papers · 2015: 4 papers · 2016: 2 papers · 2017: 3 papers · 2018: 4 papers · 2019: 8 papers · 2020: 8 papers · 2021: 12 papers · 2022: 2 papers · 2023: 8 papers · 2024: 6 papers · 2025: 7 papers · 2026: 5 papers

Papers 50 of 82

  1. Immune Markers and Risk of Pancreatic Cancer in the European EPIC Cohort. Co-author DOI 10.1002/ijc.70581↗
  2. Detection of mutated KRAS, TP53, CDKN2A, and SMAD4 in tumor cell-free DNA of Brazilian pancreatic adenocarcinoma patients using next-generation sequencing. Co-author DOI 10.1038/s41598-026-42403-4↗
  3. Polygenic scores for risk of pancreatic ductal adenocarcinoma: evaluation of novel and published models. Co-author DOI 10.1038/s41698-026-01479-x↗
  4. Different diabetes types and pancreatic ductal adenocarcinoma: a Mendelian randomization and pathway/gene-set analysis. Co-author DOI 10.1093/jnci/djaf308↗
  5. Novel Genetic Risk Loci for Pancreatic Ductal Adenocarcinoma Identified in a Genome-wide Study of African Ancestry Individuals Co-author DOI 10.64898/2026.04.21.26351329↗
  6. Polymorphisms within autophagy-related genes as susceptibility biomarkers for pancreatic cancer: A meta-analysis of three large European cohorts and functional… Co-author DOI 10.1002/ijc.35196↗
  7. Evaluating Sex Disparity in Pancreatic Ductal Adenocarcinoma Risk in the UK Biobank Cohort. Co-author DOI 10.1002/ueg2.70102↗
  8. Author's Reply: Comment on "Analysis of exposome and genetic variability suggests stress as a major contributor for development of pancreatic ductal adenocarci… Co-author DOI 10.1016/j.dld.2024.12.025↗
  9. Targeting pancreatic cancer screening by identification of pathogenic variants of BRCA2/ BRCA1 in healthy individuals who have no known family history of pancr… Co-author DOI 10.1016/j.semcancer.2025.05.001↗
  10. Allelic effects on KLHL17 expression underlie a pancreatic cancer genome-wide association signal at chr1p36.33. Co-author DOI 10.1038/s41467-025-59109-2↗
  11. A pleiotropy scan to discover new susceptibility loci for pancreatic ductal adenocarcinoma. Co-author DOI 10.1093/mutage/geae012↗
  12. Sex Disparities and Female Reproductive and Hormonal Factors Associated with Risk of Pancreatic Cancer in the European Prospective Investigation into Cancer an… Co-author DOI 10.3390/cancers17142275↗
  13. Potential association between PSCA rs2976395 functional variant and pancreatic cancer risk. Co-author DOI 10.1002/ijc.35046↗
  14. Analysis of exposome and genetic variability suggests stress as a major contributor for development of pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.dld.2023.10.015↗
  15. Genetically predicted gut bacteria, circulating bacteria-associated metabolites and pancreatic ductal adenocarcinoma: a Mendelian randomisation study. Co-author DOI 10.1038/s41598-024-77431-5↗
  16. Publisher Correction: Genetically predicted gut bacteria, circulating bacteria-associated metabolites and pancreatic ductal adenocarcinoma: a Mendelian randomi… Co-author DOI 10.1038/s41598-024-83618-7↗
  17. Polymorphisms in transcription factor binding sites and enhancer regions and pancreatic ductal adenocarcinoma risk. Last author DOI 10.1186/s40246-024-00576-x↗
  18. Physical Activity, Sedentary Behavior, and Pancreatic Cancer Risk: A Mendelian Randomization Study. Co-author DOI 10.1210/jendso/bvae017↗
  19. Association between a polymorphic variant in the CDKN2B-AS1/ANRIL gene and pancreatic cancer risk. Co-author DOI 10.1002/ijc.34383↗
  20. The PANcreatic Disease ReseArch (PANDoRA) consortium: Ten years' experience of association studies to understand the genetic architecture of pancreatic cancer. Last author DOI 10.1016/j.critrevonc.2023.104020↗
  21. Genetic and non-genetic risk factors for early-onset pancreatic cancer. Co-author DOI 10.1016/j.dld.2023.02.023↗
  22. A scan of all coding region variants of the human genome, identifies 13q12.2-rs9579139 and 15q24.1-rs2277598 as novel risk loci for pancreatic ductal adenocarc… Co-author DOI 10.1093/carcin/bgad056↗
  23. Polymorphic variants involved in methylation regulation: a strategy to discover risk loci for pancreatic ductal adenocarcinoma. Co-author DOI 10.1136/jmg-2022-108910↗
  24. Genetic Susceptibility to Nonalcoholic Fatty Liver Disease and Risk for Pancreatic Cancer: Mendelian Randomization. Co-author DOI 10.1158/1055-9965.epi-23-0453↗
  25. Exploring the Neandertal legacy of pancreatic ductal adenocarcinoma risk in Eurasians. Co-author DOI 10.1186/s40659-023-00457-y↗
  26. Role of pancreatic ductal adenocarcinoma risk factors in intraductal papillary mucinous neoplasm progression. Co-author DOI 10.3389/fonc.2023.1172606↗
  27. Germline genetic variability in pancreatic cancer risk and prognosis. First author DOI 10.1016/j.semcancer.2020.08.003↗
  28. Common variability in oestrogen-related genes and pancreatic ductal adenocarcinoma risk in women. Co-author DOI 10.1038/s41598-022-22973-9↗
  29. Genome-wide scan of long noncoding RNA single nucleotide polymorphisms and pancreatic cancer susceptibility. Co-author DOI 10.1002/ijc.33475↗
  30. A 584 bp deletion in CTRB2 inhibits chymotrypsin B2 activity and secretion and confers risk of pancreatic cancer. Co-author DOI 10.1016/j.ajhg.2021.09.002↗
  31. Lack of association of CD44-rs353630 and CHI3L2-rs684559 with pancreatic ductal adenocarcinoma survival. Co-author DOI 10.1038/s41598-021-87130-0↗
  32. Associations between pancreatic expression quantitative traits and risk of pancreatic ductal adenocarcinoma. Co-author DOI 10.1093/carcin/bgab057↗
  33. Polygenic and multifactorial scores for pancreatic ductal adenocarcinoma risk prediction. Co-author DOI 10.1136/jmedgenet-2020-106961↗
  34. Smoking Modifies Pancreatic Cancer Risk Loci on 2q21.3. Co-author DOI 10.1158/0008-5472.can-20-3267↗
  35. Are Circulating Immune Cells a Determinant of Pancreatic Cancer Risk? A Prospective Study Using Epigenetic Cell Count Measures. Co-author DOI 10.1158/1055-9965.epi-21-0169↗
  36. Genetic Polymorphisms Involved in Mitochondrial Metabolism and Pancreatic Cancer Risk. Co-author DOI 10.1158/1055-9965.epi-21-0353↗
  37. Susceptibility loci for pancreatic cancer in the Brazilian population. Last author DOI 10.1186/s12920-021-00956-5↗
  38. A multilayered post-GWAS assessment on genetic susceptibility to pancreatic cancer. Co-author DOI 10.1186/s13073-020-00816-4↗
  39. Association of Genetic Variants Affecting microRNAs and Pancreatic Cancer Risk. Last author DOI 10.3389/fgene.2021.693933↗
  40. Identification of Recessively Inherited Genetic Variants Potentially Linked to Pancreatic Cancer Risk. Last author DOI 10.3389/fonc.2021.771312↗
  41. Genome-wide association study identifies an early onset pancreatic cancer risk locus. Last author DOI 10.1002/ijc.33004↗
  42. A Transcriptome-Wide Association Study Identifies Novel Candidate Susceptibility Genes for Pancreatic Cancer. Co-author DOI 10.1093/jnci/djz246↗
  43. Mendelian randomisation study of the effects of known and putative risk factors on pancreatic cancer. Last author DOI 10.1136/jmedgenet-2019-106200↗
  44. Genome-Wide Association Study Data Reveal Genetic Susceptibility to Chronic Inflammatory Intestinal Diseases and Pancreatic Ductal Adenocarcinoma Risk. Co-author DOI 10.1158/0008-5472.can-20-0447↗
  45. Mitochondrial DNA Copy-Number Variation and Pancreatic Cancer Risk in the Prospective EPIC Cohort. Co-author DOI 10.1158/1055-9965.epi-19-0868↗
  46. Associations between Genetically Predicted Blood Protein Biomarkers and Pancreatic Cancer Risk. Co-author DOI 10.1158/1055-9965.epi-20-0091↗
  47. Genome-Wide Gene-Diabetes and Gene-Obesity Interaction Scan in 8,255 Cases and 11,900 Controls from PanScan and PanC4 Consortia. Co-author DOI 10.1158/1055-9965.epi-20-0275↗
  48. Mendelian Randomization Analysis of n-6 Polyunsaturated Fatty Acid Levels and Pancreatic Cancer Risk. Co-author DOI 10.1158/1055-9965.epi-20-0651↗
  49. CA19-9 and apolipoprotein-A2 isoforms as detection markers for pancreatic cancer: a prospective evaluation. Co-author DOI 10.1002/ijc.31900↗
  50. Genetic determinants of telomere length and risk of pancreatic cancer: A PANDoRA study. Last author DOI 10.1002/ijc.31928↗

Closest collaborators

The 25 strongest of 165 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Daniele Campa · 28 shared papers, 2011–2026 · strength 3.47
  2. Manuel Gentiluomo · 14 shared papers, 2019–2025 · strength 1.98
  3. Gabriele Capurso · 15 shared papers, 2013–2025 · strength 1.42
  4. Giulia Peduzzi · 7 shared papers, 2019–2025 · strength 1.32
  5. Riccardo Farinella · 7 shared papers, 2023–2025 · strength 1.31
  6. Cosmeri Rizzato · 10 shared papers, 2011–2025 · strength 1.00
  7. Verena Andrea Katzke · 9 shared papers, 2014–2026 · strength 0.83
  8. Lívia Archibugi · 5 shared papers, 2018–2025 · strength 0.71
  9. Rudolf Kaaks · 8 shared papers, 2012–2026 · strength 0.68
  10. Eithne Costello · 7 shared papers, 2011–2025 · strength 0.57
  11. Francesca Tavano · 9 shared papers, 2013–2023 · strength 0.57
  12. John P. Neoptolemos · 10 shared papers, 2011–2023 · strength 0.56
  13. Luca Morelli · 5 shared papers, 2020–2023 · strength 0.56
  14. Pavel Souček · 9 shared papers, 2013–2023 · strength 0.52
  15. Raffaele Pezzilli · 9 shared papers, 2013–2023 · strength 0.52
  16. Thilo Hackert · 8 shared papers, 2016–2023 · strength 0.52
  17. Stefano Landi · 8 shared papers, 2013–2023 · strength 0.51
  18. Renata Talar‐Wojnarowska · 10 shared papers, 2013–2022 · strength 0.51
  19. Mateus Nóbrega Aoki · 3 shared papers, 2021–2026 · strength 0.51
  20. William Greenhalf · 6 shared papers, 2011–2025 · strength 0.47
  21. Marta Crous‐Bou · 3 shared papers, 2021–2026 · strength 0.46
  22. Malin Sund · 7 shared papers, 2012–2025 · strength 0.45
  23. David J. Hughes · 3 shared papers, 2017–2024 · strength 0.43
  24. Beatrice Mohelníková-Duchoňová · 7 shared papers, 2013–2023 · strength 0.43
  25. Marco Calderisi · 2 shared papers, 2024–2025 · strength 0.42

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.